| Name | Brimonidine Tartrate |
| Description | Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension. |
| In vitro | Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes. |
| In vivo | Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.52 mM), Sonication is recommended.
DMSO : 16.67 mg/mL (37.7 mM), Sonication is recommended.
H2O : 56.53 mM, Sonication is recommended.
|
| Keywords | α2A-adrenergic receptor | UK-14304 Tartrate | UK-14304 | UK14304 | UK 14304 Tartrate | UK 14304 | Brimonidine Tartrate | Brimonidine | AGN-190342 Tartrate | AGN-190342 | AGN190342 | AGN 190342 Tartrate | AGN 190342 | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
